Minghao Xu

518 total citations
26 papers, 375 citations indexed

About

Minghao Xu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Minghao Xu has authored 26 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Immunology. Recurrent topics in Minghao Xu's work include Immune cells in cancer (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Cancer Research and Treatments (3 papers). Minghao Xu is often cited by papers focused on Immune cells in cancer (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Cancer Research and Treatments (3 papers). Minghao Xu collaborates with scholars based in China, Ethiopia and United States. Minghao Xu's co-authors include Chenhao Zhou, Ying‐Hao Shen, Jialei Weng, Ning Ren, Qiang Zhou, Hui‐Chuan Sun, Zhi‐Tu Zhu, Jian Gao, Guo‐Ming Shi and Ai‐Wu Ke and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and SHILAP Revista de lepidopterología.

In The Last Decade

Minghao Xu

26 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Minghao Xu China 10 217 144 90 88 51 26 375
Zike Yang China 6 219 1.0× 114 0.8× 130 1.4× 89 1.0× 46 0.9× 12 419
Anli Jin China 10 211 1.0× 115 0.8× 90 1.0× 81 0.9× 54 1.1× 15 387
Qingwen Jiang United States 2 241 1.1× 139 1.0× 163 1.8× 68 0.8× 64 1.3× 3 452
Tao Ji China 13 252 1.2× 164 1.1× 69 0.8× 34 0.4× 29 0.6× 32 414
Mengchuan Wang China 13 274 1.3× 175 1.2× 106 1.2× 46 0.5× 60 1.2× 22 472
Tianxiu Dong China 12 211 1.0× 103 0.7× 96 1.1× 57 0.6× 36 0.7× 19 373
Carmen Oi Ning Leung Hong Kong 9 265 1.2× 97 0.7× 88 1.0× 52 0.6× 50 1.0× 17 405
Renle Du China 13 231 1.1× 109 0.8× 140 1.6× 107 1.2× 53 1.0× 24 429
Florence Giffard France 13 320 1.5× 173 1.2× 90 1.0× 43 0.5× 54 1.1× 23 454
Filipa Martins Portugal 8 205 0.9× 135 0.9× 93 1.0× 41 0.5× 61 1.2× 13 378

Countries citing papers authored by Minghao Xu

Since Specialization
Citations

This map shows the geographic impact of Minghao Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minghao Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minghao Xu more than expected).

Fields of papers citing papers by Minghao Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minghao Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minghao Xu. The network helps show where Minghao Xu may publish in the future.

Co-authorship network of co-authors of Minghao Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Minghao Xu. A scholar is included among the top collaborators of Minghao Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minghao Xu. Minghao Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yanbo, Minghao Xu, Johannes E. Erchinger, et al.. (2025). A General Three-Component Nozaki–Hiyama–Kishi-Type Reaction Enabled by Delayed Radical-Polar Crossover. Journal of the American Chemical Society. 147(3). 2642–2652. 10 indexed citations
2.
Xu, Minghao, Yi-Min Zheng, Junbo Chen, et al.. (2025). CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma. Cell Reports Medicine. 6(7). 102208–102208. 1 indexed citations
3.
Xu, Minghao, Yanbo Li, Huamin Wang, Frank Glorius, & Xiaotian Qi. (2025). Mechanism Switch Between Radical‐Polar Crossover and Radical Buffering. Angewandte Chemie. 137(21). 1 indexed citations
4.
Xu, Minghao, Yanbo Li, Huamin Wang, Frank Glorius, & Xiaotian Qi. (2025). Mechanism Switch Between Radical‐Polar Crossover and Radical Buffering. Angewandte Chemie International Edition. 64(21). e202500522–e202500522. 4 indexed citations
5.
He, Yu‐Ping, Minghao Xu, Chenhao Zhou, et al.. (2024). The Prognostic Significance of CTSV Expression in Patients with Hepatocellular Carcinoma. International Journal of General Medicine. Volume 17. 4867–4881. 3 indexed citations
6.
7.
Weng, Jialei, Zheng Wang, Zhiqiu Hu, et al.. (2024). Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy. Cancer Research. 84(11). 1817–1833. 18 indexed citations
8.
Xu, Wenxin, Jialei Weng, Minghao Xu, et al.. (2024). Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization. Cancer Immunology Immunotherapy. 73(3). 56–56. 8 indexed citations
9.
10.
Yang, Shiguang, Min Xu, Jialei Weng, et al.. (2024). WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy. Journal for ImmunoTherapy of Cancer. 12(11). e010422–e010422. 6 indexed citations
11.
Wang, Pei, et al.. (2024). CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils. Journal of Hepatocellular Carcinoma. Volume 11. 787–800. 8 indexed citations
12.
Weng, Jialei, Shaoqing Liu, Qiang Zhou, et al.. (2023). Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 11(6). e006655–e006655. 32 indexed citations
13.
Xu, Minghao, Cheng Huang, Xiao‐Dong Zhu, et al.. (2023). Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study. Cancer Medicine. 12(8). 9202–9212. 8 indexed citations
14.
Weng, Jialei, Minghao Xu, Qiang Zhou, et al.. (2023). Functions of Key Enzymes of Glycolytic Metabolism in Tumor Microenvironment. Cellular Reprogramming. 25(3). 91–98. 10 indexed citations
15.
Xu, Minghao, Bin Xu, Chenhao Zhou, et al.. (2022). An mALBI-Child–Pugh-based nomogram for predicting post-hepatectomy liver failure grade B–C in patients with huge hepatocellular carcinoma: a multi-institutional study. World Journal of Surgical Oncology. 20(1). 206–206. 5 indexed citations
16.
Xu, Minghao, Chenhao Zhou, Jialei Weng, et al.. (2022). Tumor associated macrophages-derived exosomes facilitate hepatocellular carcinoma malignance by transferring lncMMPA to tumor cells and activating glycolysis pathway. Journal of Experimental & Clinical Cancer Research. 41(1). 253–253. 106 indexed citations
17.
Wang, Yuanyuan, et al.. (2021). Abnormal arginine metabolism is associated with prognosis in patients of gastric cancer. Translational Cancer Research. 10(5). 2451–2469. 9 indexed citations
18.
Zhou, Qiang, Hao Cai, Minghao Xu, et al.. (2020). Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?. Hepatobiliary & pancreatic diseases international. 20(1). 13–20. 11 indexed citations
19.
Wang, Zhenghua, et al.. (2020). IL-7R gene variants are associated with breast cancer susceptibility in Chinese Han women. International Immunopharmacology. 86. 106756–106756. 2 indexed citations
20.
Hu, Lu, Yu Gao, Yun‐Feng Cao, et al.. (2016). Association of plasma arginine with breast cancer molecular subtypes in women of Liaoning province. IUBMB Life. 68(12). 980–984. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zike Yang Breakdown of academic impact, for papers by Anli Jin Breakdown of academic impact, for papers by Qingwen Jiang Breakdown of academic impact, for papers by Tao Ji Breakdown of academic impact, for papers by Mengchuan Wang Breakdown of academic impact, for papers by Tianxiu Dong Breakdown of academic impact, for papers by Carmen Oi Ning Leung Breakdown of academic impact, for papers by Renle Du Breakdown of academic impact, for papers by Florence Giffard Breakdown of academic impact, for papers by Filipa Martins
Rankless by CCL
2026